ArticleScience translational medicine2018
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 105 citations in OpenAlex.
- Synergistic epigenetic modulation and ferroptosis induction via codelivery of Decitabine and Sorafenib for potent anti-tumor therapy.Drug delivery · 2026Article
- The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- Identification and validation of an endoplasmic reticulum stress related model to predict prognosis and tumor microenvironment in neuroblastoma.BMC cancer · 2026Article
- Anti-tumor effects and mechanism of the histone demethylase inhibitor GSK-J4 in non-small cell lung cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma.Cancer research · 2025Article
- JMJD3-mediated senescence is required to overcome stress-induced hematopoietic defects.EMBO reports · 2025Article
- Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth.Cell death & disease · 2025Article
- Review
- Epigenetic dynamics in meniscus cell migration and its zonal dependency in response to inflammatory conditions.APL bioengineering · 2025Article
- JMJD3 deficiency disturbs dopamine biosynthesis in midbrain and aggravates chronic inflammatory pain.Acta neuropathologica communications · 2024Article
- Mutation on JmjC domain of UTX impaired its antitumor effects in pancreatic cancer via inhibiting G0S2 expression and activating the Toll-like signaling pathway.Molecular medicine (Cambridge, Mass.) · 2024Article
- Epigenetic Dynamics in Meniscus Cell Migration and its Zonal Dependency in Response to Inflammatory Conditions: Implications for Regeneration Strategies.bioRxiv : the preprint server for biology · 2024Article
- Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.Cell reports. Medicine · 2024Article
- Antitumoral Potential of the Histone Demethylase Inhibitor GSK-J4 in Retinoblastoma.Investigative ophthalmology & visual science · 2024Article
- Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation inJournal of the Endocrine Society · 2024Article
- Article
- Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4.Cancers · 2023Article
- Targeting the epigenome of cancer stem cells in pediatric nervous system tumors.Molecular and cellular biochemistry · 2023Review
- Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Timothy L LochmannVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.ORCID 0000-0002-3368-6067
Krista M PowellVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
Jungoh HamVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
Konstantinos V FlorosVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.ORCID 0000-0003-4916-2257
Daniel A R HeiseyVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.ORCID 0000-0002-5702-1000
Richard I J KurupiVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
Marissa L CalbertVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
Maninderjit S GhotraVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA.
Patricia GreningerCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Mikhail DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-0086-8358
Madhu GowdaDivision of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA 23298, USA.
Andrew J SouersAbbVie, 1 North Waukegan Road, North Chicago, IL 60064, USA.
C Patrick ReynoldsCancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79430, USA.ORCID 0000-0002-2827-8536
Cyril H BenesCenter for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. acfaber@vcu.edu cbenes@mgh.harvard.edu.ORCID 0000-0002-8751-9707
Anthony C FaberVirginia Commonwealth University Philips Institute, School of Dentistry and Massey Cancer Center, Richmond, VA 23298, USA. acfaber@vcu.edu cbenes@mgh.harvard.edu.ORCID 0000-0002-7246-4272
Virginia Commonwealth University · USHarvard University · USAbbVie (United States) · USChildren's Hospital of Richmond at VCU · USTexas Tech University · US
Funding
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0MABT-199 based therapies to treat neuroblastomaR01CA215610 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Anthony Charles Faber · 2017 to 2026
$2.9MNCI NIH HHS P30 CA016059NCI NIH HHS R01 CA215610Wellcome Trust 102696Wellcome Trust 102696STRATTON
Abstract
High-risk neuroblastoma is often distinguished by amplification of
Indexed as
DemethylationAnimalsAxonsBenzazepinesBridged Bicyclo Compounds, HeterocyclicCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHistone DemethylasesHistonesHumansLysineMice, NudeNeuroblastomaBenzazepinesBridged Bicyclo Compounds, HeterocyclicGSK-J4Histone DemethylasesHistonesLysinePyrimidinesSulfonamidesTretinoinvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.